As of March 26, 2026, Ledipasvir does not have an official monograph in the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), or Indian Pharmacopoeia (IP). In the absence of a specific monograph, general pharmacopoeial standards apply to ensure the quality, safety, and efficacy of the drug.
- Purity/Assay Requirements: General pharmacopoeial standards require that the active pharmaceutical ingredient (API) meets specified purity criteria, typically assessed through assays that quantify the drug substance's content.
- Dissolution Testing: For solid oral dosage forms, dissolution testing is crucial to ensure consistent drug release. The USP General Chapter <711> outlines procedures for dissolution testing, including apparatus selection, dissolution medium, and acceptance criteria.
- Stability Testing per ICH Zones: Stability testing evaluates how the quality of a drug substance or product varies with time under the influence of environmental factors. The International Council for Harmonisation (ICH) guidelines define different climatic zones (I-IV) to account for global climatic variations, ensuring that stability data is relevant to the regions where the product will be distributed.
In summary, while Ledipasvir lacks specific monographs in major pharmacopoeias, adherence to general pharmacopoeial standards and ICH guidelines is essential to ensure its quality and compliance in international markets.